Welcome to our dedicated page for CervoMed SEC filings (Ticker: CRVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CervoMed Inc. filings document a clinical-stage biotechnology issuer focused on neflamapimod and age-related brain disorders. Form 8-K reports include Regulation FD disclosures, press release exhibits, operating and financial results, and updates on clinical studies such as RewinD-LB in dementia with Lewy bodies, pharmacokinetic work, biomarker analyses, and ALS platform inclusion.
Proxy materials describe shareholder voting matters, board and governance practices, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also identifies CRVO common stock on the Nasdaq Capital Market and provides capital-structure, business-development, and financial-position disclosures relevant to CervoMed's drug-development model.
CervoMed Inc. (CRVO) reported insider share purchases by a senior executive. The company’s CFO, General Counsel and Secretary bought 1,000 shares of common stock on 11/17/2025 at $8.45 per share and 2,500 shares on 11/18/2025 at a weighted average price of $8.32 per share in open‑market transactions. Following these transactions, the reporting person beneficially owned 12,500 shares of CervoMed common stock directly.
The filing notes that the 2,500 shares purchased on 11/18/2025 were acquired at prices ranging from $8.26 to $8.38, with the weighted average price reported, and that detailed trade breakdowns are available upon request.
CervoMed Inc. (CRVO) reported insider share purchases by its CEO & President, who is also a director and 10% owner. On 11/17/2025, the reporting person bought 10,807 shares of common stock in open‑market transactions at a weighted average price of $8.46, with actual prices ranging from $8.39 to $8.46. Following this, the reporting person directly beneficially owned 1,484,078 shares.
On the same date, an additional 10,793 shares were purchased at a weighted average price of $8.46 (with prices from $8.38 to $8.50) for the reporting person’s spouse’s IRA, which is reported as indirect ownership of 12,500 shares. The ownership totals also include shares held jointly with the spouse and in a Roth IRA.
CervoMed Inc. (CRVO) reported insider share purchases by a major holder. A director and 10% owner bought 4,447 shares of common stock on 11/13/2025 at $7.51 per share in open-market transactions. On 11/14/2025, additional purchases included 1,707 shares at a weighted average price of $7.57 through the Sylvie Gregoire Roth IRA and 1,693 shares at a weighted average price of $7.55 through the John J. Alam Roth IRA.
After these transactions, the reporting person beneficially owned 1,471,578 shares of CervoMed common stock directly, with 1,693 shares held indirectly through a spouse's IRA. Some shares are held jointly with the reporting person's spouse, Dr. John Alam, the company's President & Chief Executive Officer and a member of the Board of Directors.
CervoMed Inc. (CRVO) reported insider buying by its CEO, President, director and 10% owner. On 11/13/2025, the reporting person bought 4,447 shares of common stock in open-market transactions at $7.51 per share. On 11/14/2025, additional open-market purchases included 1,693 shares at a weighted average price of $7.55 through the John J. Alam Roth IRA and 1,707 shares at a weighted average price of $7.57 through the Sylvie Gregoire Roth IRA. Following these transactions, 1,471,578 shares were held jointly by the reporting person and his spouse, Dr. Sylvie Gregoire, with separate Roth IRA holdings noted.
CervoMed Inc. (CRVO) reported an insider transaction in which its Chief Commercial and Business officer purchased 10,000 shares of common stock in open-market transactions on 11/14/2025 at a weighted average price of $7.57 per share. Following this transaction, the reporting person beneficially owns 10,000 shares, held directly.
According to the filing, the shares were bought in multiple open-market trades at prices ranging from $7.53 to $7.60 per share. The reporting person has undertaken to provide full details of the number of shares purchased at each separate price within this range upon request.
CervoMed Inc. (CRVO) reported an insider transaction on a Form 4. A director and 10% owner purchased 5,553 shares of common stock in open‑market transactions on 11/12/2025 at a price of $7.35 per share. Following the purchase, the reporting person beneficially owned 1,467,131 shares. The filing notes these shares are held jointly with the reporting person’s spouse, Dr. John Alam, M.D., the company’s President & Chief Executive Officer and a member of the Board of Directors.
CervoMed Inc. (CRVO) reported an insider stock purchase by its CFO, GC & Secretary, William R. Elder. On 11/12/2025, Elder bought 3,500 shares of common stock in open‑market transactions at $7.44 per share (Transaction Code: P). Following the transaction, his direct holdings total 9,000 shares. The filing was submitted by one reporting person.
CervoMed Inc. (CRVO) insider purchase: The CEO & President, who is also a Director and 10% Owner, bought 5,553 shares of common stock at $7.35 on 11/12/2025 in open‑market transactions. Following the purchase, he beneficially owned 1,467,131 shares, reported as directly held. The filing notes these shares are held jointly by the reporting person and his spouse, Dr. Sylvie Gregoire, PharmD, a member of the Board of Directors.
CervoMed Inc. furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference. The disclosure is provided under Item 2.02 and is being furnished, not deemed “filed” for purposes of Section 18 of the Exchange Act. CervoMed’s common stock trades on the NASDAQ Capital Market under the symbol CRVO.
CervoMed Inc. filed a Form S-8 to register 800,000 shares of common stock for issuance under its 2025 Equity Incentive Plan, and 129,000 shares of common stock issuable upon exercise of previously announced non-qualified stock option inducement awards granted on June 9, 2025 and October 6, 2025 in accordance with Nasdaq Listing Rule 5635(c)(4).
The filing incorporates CervoMed’s recent 10-Qs for the quarters ended March 31, June 30, and September 30, 2025, and multiple 8-Ks filed in 2025. It also summarizes the company’s Delaware-law indemnification framework for directors and officers and lists exhibits including the legal opinion, auditor consent, and plan documents.